Johannes Holzmeister

Chief Executive Officer at Cardiorentis AG

Health Technology

Profile

Johannes Holzmeister currently works at Cardiorentis AG, as Chairman & Chief Executive Officer and DiNAQOR AG, as Chairman & Chief Executive Officer.

Johannes Holzmeister active positions

Companies	Position	Start
Cardiorentis AG Cardiorentis AG Pharmaceuticals: MajorHealth Technology Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland.	Chief Executive Officer	-
DiNAQOR AG DiNAQOR AG BiotechnologyHealth Technology DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister.	Chief Executive Officer	-

All active positions of Johannes Holzmeister

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Johannes Holzmeister's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Cardiorentis AG Cardiorentis AG Pharmaceuticals: MajorHealth Technology Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland.	Health Technology
DiNAQOR AG DiNAQOR AG BiotechnologyHealth Technology DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister.	Health Technology